trichomonas vaginalis

Metronidazole (Metronidazol) is a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities.

α,γ-Homocysteinase, Trichomonas vaginalis is a pyridoxal-5'-phosphate-dependent enzyme. It represents a mutant form of Trichomonas vaginalis homocysteine lyase encoded by the mgl1 gene and contains three point mutations: Phe47Leu, Asp172Glu, and Ser308Tyr. This enzyme catalyzes the conversion of homocysteine into α-ketobutyrate, hydrogen sulfide, and ammonia.

SQ109 (NSC 722041) is an ethambutol (EMB) derivative and a specific inhibitor of MmpL3, exhibiting potent anti-Mycobacterium tuberculosis activity. SQ109 effectively inhibits the adult stage of the parasite Trypanosoma and kills cells, with an IC50 of 50 ± 8 nM. SQ109 can be used in tuberculosis and antiparasitic research.

RR-11a analog (aza-peptide Michael acceptor, 7a) is an inhibitor of asparaginyl endopeptidase with IC50s of 4.5 nM, 4.5 nM and 31 nM for AE1 in Trichomonas Vaginalis, AE in Ixodes ricinus and AE in Schistosoma mansoni, respectively.

Sulnidazole, a nitroimidazole derivative, functions as an antiprotozoal compound effective against Trichomonas vaginalis.

Stirimazole, an imidazole derivative, has demonstrated the ability to inhibit Trichomonas vaginalis in vitro at an effective concentration of 0.225 μg/ml. In animal studies, an oral dose of 20 mg/kg successfully eradicated infectious lesions in mice.

Fexinidazole (HOE 239) is an antiparasitic agent with activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis, Entamoeba histolytica, Trypanosoma brucei, and Leishmania donovani. The biologically relevant active metabolites in vivo are the sulfoxide and sulfone.

Carmaphycin-17 (CP-17) is a selective proteasome inhibitor with an EC50 of 217 nM. It exhibits potent antimicrobial activity against Trichomonas vaginalis and can overcome resistance to Metronidazole. In mouse models of vaginal trichomoniasis, CP-17 significantly reduces parasite burden after topical treatment without any observed adverse effects. Additionally, Carmaphycin-17 is useful for researching sexually transmitted diseases like trichomoniasis.

Coriolin A exhibits activity against gram-positive bacteria, weakly against gram-negative bacteria, as well as yeasts and Trichomonas vaginalis. At a concentration of 5 μg/mL, it inhibits 61.6% of the growth of Yoshida sarcoma, but shows no inhibitory effect on Ehrlich ascites carcinoma in animals.

Granaticin A inhibits the initial stages of RNA biosynthesis and exhibits activity against Gram-positive bacteria, mycobacteria (weak), and Trichomonas vaginalis, as well as tumor cells.

Granaticin B inhibits the initial phase of RNA biosynthesis and exhibits activity against Gram-positive bacteria, mycobacteria (weak), and Trichomonas vaginalis, along with the ability to suppress tumor cells.

Coriolin B exhibits activity against Gram-positive bacteria, weak activity against Gram-negative bacteria, yeast, and Trichomonas vaginalis. At a concentration of 5 μg/mL, Coriolin B inhibits 61.6% of Yoshida sarcoma growth but shows no inhibitory effect on Ehrlich ascites carcinoma in animals.

Coriolin C displays activity against Gram-positive bacteria, weakly against Gram-negative bacteria, as well as yeast and Trichomonas vaginalis. At a concentration of 5 μg/mL, Coriolin C can inhibit 61.6% of the growth of Yoshida sarcoma, though it does not affect Ehrlich ascites carcinoma in animals.

5'-Azido-5'-deoxyadenosine is a purine nucleoside analogue containing an azide group, exhibiting inhibitory activity against Trichomonas vaginalis and PRMT5, and capable of undergoing click chemistry reactions with molecules containing alkyne, DBCO, or BCN groups.

LL-37 FK-13 TFA, the TFA salt form of LL-37 FK-13, is an antimicrobial agent that inhibits Trichomonas vaginalis. It exhibits minimal hemolytic effects on human red blood cells and shows slight cytotoxicity towards human fibroblasts.